The 6 analysts offering 12-month price forecasts for NGM Biopharmaceuticals Inc have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 2.00. The median estimate represents a +450.46% increase from the last price of 1.09.
The current consensus among 6 polled investment analysts is to Buy stock in NGM Biopharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.42
Reporting Date Nov 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.